Table 2.
Assays for Tg Measurement by LC-MS/MS Peptide Immunoaffinity Purification.
| Ref. | Year | Antibody Peptidea | Internal Standardb | Reported Sensitivity | Additional Method Aspectsc |
|---|---|---|---|---|---|
| [11] | 2008 | Polyclonal (rabbit) anti-VIF | tSIL Peptide | LOD: 2.6 ng/mL | |
| [18] | 2012 | Polyclonal (chicken) anti-VIF | tSIL Peptide | LOD: 0.3 ng/mL, LLOQ: 0.4 ng/mL | |
| [19] | 2013 | Polyclonal anti-VIF | cSIL Peptide | LLOQ: 0.5 ng/mL | Protein Precipitation |
| [15] | 2020 | Monoclonal anti-FSP d | cSIL Peptide | LOD: 0.0057 ng/mL LLOQ: 0.02 ng/mL |
Micro-flow chromatography |
| Current method | Monoclonal anti-FSP d | tSIL Peptide | LLOQ: 0.15 ng/mL | Mobile Phase DMSO | |
a
Tg tryptic peptides: VIF, VIFDANAPVAVR; FSP, FSPDDSAGASALLR.
b
Reported assays all employ multi-point external calibration, but may differ by internal standard approach, utilizing either tryptic stabile isotope labeled (tSIL) or cleavable/“winged” stable isotope labeled (cSIL) peptide.
c
All methods use protein digestion and peptide IAE. The method in Ref. 19 also uses an initial protein precipitation step.
d
Clinical Proteomic Tumor Analysis Consortium (CPTAC) antibody against FSPDDSAGASALLR sequence peptide.